Temisis Therapeutics

Temisis Therapeutics ("Temisis") is a pre-clinical stage biotechnology company developing innovative drugs derived from natural sources for the treatment of auto-immune and chronic inflammatory diseases, with an initial focus on psoriasis. Temisis most advanced compound, TEM-2085, a potential first-in-class and orally bioavailable small molecule, has demonstrated highly promising preclinical efficacy and safety profile in animal model of psoriasis, in comparison to apremilast (Otezla TM) and deucravacitinib (Sotyktu TM), both Standard of Care (SOC) for patients with mild to moderate plaque psoriasis. In addition, TEM-2085 exhibited strong and better protective effect than upadacitinib (Rinvoq TM) against colitis in rodent, a form of Inflammatory Bowel Disease (IBD), which indicates this compound has therapeutic potential for other autoimmune/inflammatory diseases. TEM-2085 and its analogues act through a novel and breakthrough mechanism of action (MoA) downmodulating the release of key proinflammatory cytokines. Founded in December 2017, Temisis is based in Nancy and is a subsidiary of Plant Advanced Technologies ("PAT"), a plant-based biotechnology company specialized in the discovery and eco-friendly production of hard-to-source plant active extracts for the cosmetic, nutraceutical, agro-chemical and biotechnology markets.”